secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0001839882-23-022729
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adamis Pharmaceuticals enters CEO employment agreement with Ebrahim Versi, M.D., Ph.D.
--------------------------------------------------------------------------------

- Base salary of $585K/year effective from May 25, 2023 merger closing; lump sum retroactive payment for prior period.
- Target annual bonus of 60% of base salary; eligibility for discretionary bonuses and equity awards.
- Termination without cause or for good reason yields 18 months salary continuation (or lump sum if within 12 months before/after change in control).
- Change in control triggers full vesting acceleration of all stock options and RSUs.
- Severance includes COBRA premium coverage for up to 18 months, subject to release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000183988223022729/0001839882-23-022729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000183988223022729/admp-8k_082323.htm
  HTML page:      https://secwatch.observer/filing/0001839882-23-022729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer